GlobeNews Wire

TransAlta Signs Long-Term Agreement for 700 MW at Centralia Facility Enabling Coal to Natural Gas Conversion

December 09, 2025 07:00 ET  | Source: TransAlta Corporation CALGARY, Alberta, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Highlights TransAlta to…

1 month ago

Aeluma Files New Patent That Enhances Intellectual Property for Large-Scale High Performance Semiconductor Manufacturing

Strengthens Aeluma’s Heterogeneous Integration Platform and Expands Intellectual Property Portfolio to 35 Issued and Pending Patents December 09, 2025 07:00…

1 month ago

Zelluna ASA – Mandatory notification of trade

Reference is made to the private placement (the "Private Placement") and the retail offering through PrimaryBid announced by Zelluna ASA on…

1 month ago

Ipsen – November 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8…

1 month ago

Nelipak Acquires Merrills Packaging

CRANSTON, R.I., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Nelipak® Corporation (“Nelipak”), a leading global provider of healthcare packaging solutions, announced…

1 month ago

Aurora Mobiles EngageLab Launches AI-Powered Customer Service Platform LiveDesk, Revolutionizing Enterprise Customer Experience

SHENZHEN, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading…

1 month ago

Mercury Showcases Expanding Portfolio of Electronic Warfare Capabilities at AOC 2025

December 08, 2025 07:00 ET  | Source: Mercury Systems Inc ANDOVER, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Mercury Systems,…

1 month ago

The Acceleration Continues: Vetty Named One of Nucleus Researchs Hot Companies to Watch in 2026

AUSTIN, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vetty, the one-stop shop hiring acceleration platform, announced today that it was…

1 month ago

Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial…

1 month ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…

1 month ago